Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
Zenas BioPharma (Nasdaq: ZBIO) said new data from the Phase 3 INDIGO trial of obexelimab in IgG4-related disease will be presented at the 6th International Symposium on IgG4-Related Disease (October 8-10, Cambridge, MA) and ACR Convergence 2026 (November 6-11, Orlando, FL). The lineup includes longer-term flare protection and safety data from the INDIGO open-label extension, plus analyses of glucocorticoid-associated toxicity and of influenza and SARS-CoV-2 vaccine responses in treated patients. Obexelimab has been evaluated in nine clinical trials totaling 667 subjects; IgG4-RD affects roughly 20,000 diagnosed patients in the US, with true prevalence estimated closer to 40,000.
Key figures
- Drug Name
- obexelimab
- Phase Of Trial
- Phase 3
- Clinical trials to date
- 9
- Sunstone topline timing
- 4Q 2026
- Total subjects evaluated
- 667
- Estimated us igg4rd patients
- 40000
- Us diagnosed igg4rd patients
- 20000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.